August 1 is the deadline to register if you wish to receive printed course material on-site (if it is provided by the instructor(s)).
The Short Courses for MSACL 2025 will be held only In-Person.
Short courses will be from 8-16 hrs.
Continuing Medical Education (CME) is anticipated to be offered.
You MUST be registered for the conference in order to attend a Short Course. Short Courses have an additional fee.
Short Course Pricing (per HOUR):
EarlyBird by Jun 18, 2025
Regular after Jun 18, 2025
Late after Jul 23, 2025
über-Late after Sep 07, 2025
Industry
USD$45/h
USD$50/h
USD$60/h
CLOSED
Academic
USD$35/h
USD$38/h
USD$41/h
CLOSED
Student
USD$13/h
USD$16/h
USD$20/h
CLOSED
All courses are IN-PERSON only.
All short courses are anticipated to include Continuing Medical Education (CME) AMA PRA Category 1 Credit™. The amount of credit assigned to each course may be slightly less than the contact hours stated due to hourly breaks.
*Note : You can take more than one course if they don't overlap. Use segment times listed under the course to coordinate.
Course Offering
Admin Alert: Two or more courses have the same place-order. This needs to be corrected to achieve a proper flow of the course profiles below.
Financial Disclosures (past 24 months as of Jan 29, 2025) Other Conflicts: Labcorp / Employee
Labcorp / Stock
The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality.
Matthew Campbell, PhD Labcorp
Financial Disclosures (past 24 months as of Jan 29, 2025) Other Conflicts: Labcorp / Employee
The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality.
Dr. Hoofnagle's laboratory focuses on the precise quantification of recognized protein biomarkers in human plasma using LC-MRM/MS. In addition, they have worked to develop novel assays for the quantification of small molecules in clinical and research settings. His laboratory also studies the role that the systemic inflammation plays in the pathophysiology of obesity, diabetes, and cardiovascular disease.
Financial Disclosures (past 24 months)
: Not reported
Cory Bystrom, PhD Ultragenyx
Financial Disclosures (past 24 months)
: Not reported
Salary: Ultragenyx
Christopher Shuford, PhD Labcorp
Chris Shuford, Ph.D., is Associate Vice President and Technical Director for research and development at Laboratory Corporation of America in Burlington, North Carolina. Chris received his B.S. in Chemistry & Physics at Longwood University and obtained his Ph.D. in Bioanalytical Chemistry from North Carolina State University under the tutelage of Professor David Muddiman, where his research focused on applications of nano-flow chromatography for multiplexed peptide quantification using protein cleavage coupled with isotope dilution mass spectrometry (PC-IDMS). In 2012, Chris joined LabCorp’s research and development team where his efforts have focused on development of high-flow chromatographic methods (>1 mL/min) for multiplexed and single protein assays for clinical diagnostics.
Financial Disclosures (past 24 months as of Feb 05, 2025) Other Conflicts: Laboratory Corporation of America / Employee / Stock
The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality.
2495
Data Science 101 : Breaking Up with Excel @ Montreal 5
2469
Data Science 203 : Machine Learning : A Gentle Introduction @ Montreal 4
Stephen Master, MD, PhD, FADLM Children's Hospital of Philadelphia
Stephen Master received his undergraduate degree in Molecular Biology from Princeton University, and subsequently obtained his MD and PhD from the University of Pennsylvania School of Medicine. After residency in Clinical Pathology at Penn, he stayed on as a faculty member with a research focus in mass spectrometry-based proteomics as well as extensive course development experience in bioinformatics. After time as an Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine in New York City, where he served as Director of the Central Lab and Chief of Clinical Chemistry Laboratory Services, he took a position at the Children's Hospital of Philadelphia at Chief of Lab Medicine. One of his current interests is in the applications of bioinformatics and machine learning for the development of clinical laboratory assays. He would play with R for fun even if he weren't getting paid, but he would appreciate it if you didn't tell that to his department chair.
Financial Disclosures (past 24 months as of Feb 17, 2025) Other Conflicts: Roche Diagnostics / Advisory Board / Ended
Indigo BioAutomation / Medical Advisory Board / Ongoing
The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality.
Randall Julian, PhD Indigo BioAutomation
Randy Julian is the Founder and CEO of Indigo BioAutomation. Randy earned a Ph.D. in Chemistry from Purdue University. Dr. Julian worked for 14 years at Eli Lilly using mass spectrometry in natural product drug discovery, high throughput screening for RNA anti-viral compounds, and proteomics and metabolomics in animal models. Randy founded Indigo as a spin-out of Lilly. Indigo develops software that uses machine learning techniques to automatically analyze data from laboratories world-wide. Indigo's technology also drives new stand-alone medical devices, bringing advanced data analysis to every level of the clinical lab. Dr. Julian is also is an Adjunct Professor of Chemistry at Purdue.
Financial Disclosures (past 24 months as of Feb 05, 2025) Other Conflicts: Indigo BioAutomation, Inc. / Employee
Indigo BioAutomation, Inc. / Stock
The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality.
2475
Glyco(proteo)mics 101 : Clinical Glyco(proteo)mics by Mass Spectrometry @ Westmount 2
2483
Isotopes 101: Modern Isotope Ratio Analysis for Biomedical Research and Clinical Diagnostics @ Westmount 4
Cajetan Neubauer University of Colorado, Boulder
The frontiers of metabolomics & proteomics are finally merging with isotope ratio mass spectrometry, opening exciting new opportunities in our understanding of biological systems.
My lab at the University of Colorado Boulder helps pioneer related novel molecular measurements based on soft-ionization isotope ratio mass spectrometry. These advances can be used to study natural stable isotope fingerprints in metabolites, drugs, or small inorganic ions for a fascinating range of cross-disciplinary applications in life and earth sciences.
To achieve our longterm goal of making natural isotope patterns universally useful, we combine expertise in metabolomics and proteomics with advanced concepts of high precision stable isotope analysis from geochemistry.
Financial Disclosures (past 24 months as of Jan 20, 2025) Other Conflicts: Thermo Fisher Scientific / Consultant / Ended
The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality.
Dwight Matthews, Ph.D. University of Vermont
Prof. Matthews received his PhD degree in 1977 in Analytical Chemistry from Indiana University with a focus in mass spectrometry. For his Ph.D. thesis he developed the first gas chromatograph-combustion-isotope ratio mass spectrometer (GC-C-IRMS). He then began his career at Washington University School of Medicine in St. Louis in the Department of Medicine where he developed stable isotope tracer methods to study in vivo amino acid metabolism in humans centered around gas chromatography-mass spectrometry (GC-MS). Several of these methods are commonly used by investigators today. In 1986 he moved to Cornell University Medical College in New York City as a tenured Associate Professor of Biochemistry in Medicine and Surgery to continue studies of metabolism. Here his focus broadened to include studies of metabolism in conditions found commonly in surgical metabolism and energy metabolism using doubly labeled water measured by IRMS. He also directed the Core Laboratories of the General Clinical Research Center. In 1996 he moved to the University of Vermont (UVM) as a Professor of Medicine in the College of Medicine and as a Professor of Chemistry in the College of Arts and Sciences. At UVM he directed core laboratories related to mass spectrometry for the Clinical Research Center, the Vermont Genetics Network Proteomics Core Laboratory, and the Mass Spectrometry Core Laboratory in Immunobiology. During this period, he developed new proteomics methods using liquid chromatography-mass spectrometry (LC-MS) with a focus on precise measurement of stable isotopic enrichments in proteins and peptides. From 2002-2014, he was Chair of the Department of Chemistry at UVM and named the Pomeroy Professor of Chemistry. In 2019, Matthews became a Professor Emeritus of Chemistry and Medicine at UVM, but continues his research activities. Professor Matthews is a world-renown expert in the development of stable isotope tracer techniques to study metabolism in humans. He has published over 175 papers in a range of peer-reviewed journals and over 75 contributions to symposia and chapters in books, and has an H-index of 85.
Financial Disclosures (past 24 months as of Jan 22, 2025)
: none
Patrick Day, MPH, MLS (ASCP) Mayo Clinic
My background, training, and educational degrees are in Laboratory Medicine & Pathology and Public Health. I received my bachelor’s and master’s degrees both from the University of Minnesota. My MPH thesis was on how geospatial supercomputing and clinical laboratory data can be combined to study how socioeconomic determinants of health and geography within the United States are associated with elevated levels of arsenic and mercury in humans. I am currently a principal developer in the Division of Computational Pathology and Artificial Intelligence at the Mayo Clinic in Rochester, MN. Prior to this role, I was a senior developer with the Metals Laboratory at Mayo Clinic. This clinical laboratory is staffed by thirty highly specialized employees that conduct metal analysis of biologic samples as well as analyze thousands of kidney stones a year by Fourier Transform Infrared Spectroscopy (FTIR). In the Metals Laboratory, I developed numerous laboratory developed tests (LDTs) as well as managed various multidisciplinary research projects. I currently hold the academic rank of Instructor in the Mayo Clinic College of Medicine and Science. I have co-authored numerous conference abstracts and peer-reviewed articles related to metals toxicology and artificial intelligence in the clinical laboratory and was honored to receive an American Society for Clinical Pathology 40 under Forty award.
Financial Disclosures (past 24 months as of Jan 21, 2025)
: none
2485
LC-MSMS 101 : Getting Started with Quantitative LC-MSMS in the Diagnostic Laboratory @ Montreal 1-2
Grace van der Gugten, B.Sc. Chemistry Alberta Precision Laboratories
Grace discovered her love for clinical mass spectrometry when she began working at St Paul's Hospital in Vancouver in the special chemistry mass spec group with Dr. Dan Holmes in late 2010. Grace was challenged in this role but gained a wealth of knowledge and experience over her 10+ years in the SPH laboratory. She puts this experience and knowledge into use in her current role as Lab Scientist in the Newborn Screening and Biochemical Genetics lab at Alberta Precision Laboratories in Edmonton. Grace loves developing streamlined, easy to use (if possible!) clinical mass spectrometry assays; teaching others and helping others succeed; and troubleshooting (especially when the problem is solved!).
Financial Disclosures (past 24 months as of Jan 27, 2025)
: none
Deborah French, PhD, DABCC (CC, TC), FADLM UCSF
Deborah French Ph.D., DABCC (CC, TC), FADLM is a Director of Chemistry and the Director of Mass Spectrometry at the University of California San Francisco Health Clinical Laboratories. Her work currently focuses on the development and validation of LC-MS/MS assays for small molecules, specifically therapeutic drug monitoring, steroid hormones and toxicology. Deborah received her Ph.D. in biochemistry from the University of Strathclyde in Glasgow, Scotland and then completed a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, TN. She subsequently completed a ComACC Clinical Chemistry postdoctoral fellowship under the direction of Dr Alan Wu at the University of California San Francisco and is now board certified in Clinical Chemistry and Toxicological Chemistry by the American Board of Clinical Chemistry.
Financial Disclosures (past 24 months as of Jan 27, 2025) Other Conflicts: ARK Diagnostics / Consultant
Roche Diagnostics / Consultant / Ended
The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality.
Jacqueline Hubbard, PhD, DABCC Beth Israel Deaconess Medical Center, Harvard Medical School
Jacqueline Hubbard received her BS degree in Biochemistry from the University of Vermont. She then earned her MS and PhD in Biochemistry and Molecular Biology from the University of California, Riverside (UCR). Following a one year postdoc at UCR, Dr. Hubbard completed a Fellowship in Clinical Chemistry at the University of California, San Diego Health. She is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. After fellowship, she took a position as an Assistant Professor in the Department of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth and as the Assistant Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center. There, she focused on developing and validating drugs of abuse assays and SARS-CoV-2 serology testing. Next, she briefly served as a Lab Director for a small reference laboratory in PIttsburgh, PA. She then joined Beth Israel Deaconess Medical Center as the Co-Director of Clinical Chemistry and Director of Toxicology in 2024. She is also an Assistant Professor of Pathology for Harvard Medical School. Her research focus still includes mass spectrometry method development and toxicology test interpretation.
Financial Disclosures (past 24 months as of Jan 28, 2025)
: none
Grace Williams VCU Health
Financial Disclosures (past 24 months as of Jan 29, 2025)
: none
2471
LC-MSMS 203 : Validation of Quantitative LC-MS/MS Assays for Clinical and Academic Use @ Montreal 3
Joshua Hayden, PhD, DABCC, FACB Norton Healthcare
Joshua is currently the Chief of Chemistry at NortonHealthcare. He earned his PhD in chemistry from Carnegie Mellon University. He conducted postdoctoral research at Massachusetts Institute of Technology before completing a two-year clinical chemistry fellowship at University of Washington and 4 years as Assistant Professor at Weill Medical College. Joshua has special expertise developing and overseeing mass spectrometry assays in the clinical laboratory.
Financial Disclosures (past 24 months as of Jan 23, 2025) Other Conflicts: BioPorto / Advisory Board / Ended
Thermo / speaker
The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality.
Claire Knezevic, PhD Lurie Childrens Hospital
Dr. Claire Knezevic is a clinical chemist in the Department of Pathology and Laboratory Medicine at Lurie Children's Hospital with a focus on chemistry, point-of-care testing, quality improvement, drug monitoring, and personalized medicine. She is an Associate Professor in Northwestern's Feinberg School of Medicine in the Department of Pathology. Her interests include all things small molecule, from toxicology to therapeutic drug monitoring and their impacts on clinical care.
Financial Disclosures (past 24 months as of Jan 21, 2025)
: none
2479
LC-MSMS 302 : Advanced LC-MSMS Method Development, Trouble-shooting and Operation for Clinical Analysis @ Montreal 6-8
Robert Voyksner, PhD LCMS Limited
Dr. Robert D. Voyksner received his B.S. in Chemistry at Canisius College in 1978 and his Ph.D. at the University of North Carolina at Chapel Hill in 1982. He was employed at Research Triangle Institute (RTI) from 1983-2001 as the director of the mass spectrometry facility and has been responsible for developing
extraction, separation and mass spectrometric methods for biologically and environmentally significant compounds. His work earned him the Presidents Award, the highest award within RTI. In 2001 he co-founded LCMS Limited in Durham, NC and has been the CEO of the company to date. Under his direction LCMS Limited is working on technological advancements in LC-MS/MS, offering services to pharmaceutical, clinical and agrochemical industry for solving unique problems by LC/MS/MS and offering training in LC/MS/MS and MS/MS interpretation and on LC/MS/MS instrumentation. Dr Voyksner is also an Adjunct professor at the North Carolina a School of Veterinary Medicine and at The University of North Carolina
School of Pharmacy.
Dr. Voyksner's research in mass spectrometry has resulted in over 230 publications and presentations, primarily in the area of LC-MS/MS. He has served on the Board of Directors for The American Society For Mass Spectrometry (ASMS), is on the organization committee for The Montreux LC/MS Symposium and was the organizer for the 1995, 1999, 2003 and 2007 Montreux LC/MS Symposia. Dr. Voyksner has taught over 100 courses on LC-MSMS, CE/MS and CID interpretation during the past 10 years for MSACL, ASMS, pharmaceutical companies; ISSX, PBA, HPCE and HPLC focused meetings.
Financial Disclosures (past 24 months as of Jan 18, 2025)
: none
2489
Lipidomics 101 : Mass Spectrometry-based Lipidomics and Clinical Applications @ Westmount 3
Anne K. Bendt, PhD Singapore Lipidomics Incubator (SLING), National University of Singapore
Anne K Bendt studied Biology focusing on marine biotechnology (Greifswald University, Germany), followed by a PhD in Biochemistry (Cologne University, Germany) employing proteomics and transcriptomics. Driven by her fascination for infectious diseases, she joined the National University of Singapore (NUS) in 2004 to develop lipidomics tools for tuberculosis studies. She is now a Principal Investigator at the Life Sciences Institute, NUS, focussing on translation of mass spec technologies into clinical applications, and serving as the Deputy Director of the Singapore Lipidomics Incubator (SLING) taking care of operations and commercialization.
Financial Disclosures (past 24 months as of Jan 19, 2025)
: none
Amaury Cazenave Gassiot, PhD Singapore Lipidomics Incubator (SLING) and Department of Biochemistry, National University of Singapore
Research Assistant Prof. Cazenave-Gassiot is an early-career researcher and an expert in mass spectrometry-based lipidomics. He graduated with a PhD in analytical chemistry at the University of Southampton (UK), under the supervision of Dr John Langley, specialising in supercritical fluid chromatography and mass spectrometry. His interest in lipids started while a postdoc in the team of Professor Anthony Postle, still in Southampton. A member of SLING since 2009, his research centres on separation sciences, mass spectrometry, and their applications to life sciences, especially lipid biochemistry. He has developed chromatographic and mass spectrometric methods for the identification and quantification of lipids in diverse biological systems. This has included successful local and international collaborations.
Financial Disclosures (past 24 months as of Jan 20, 2025)
: none
Michael Chen, MD MSc The University of British Columbia
Dr. Michael Chen is a clinical pathologist, specializing in clinical chemistry and translational mass spectrometry. He is the Division Head of Medical Biochemistry at Island Health and Provincial Discipline Lead at Provincial Health Services Authority. As a researcher, Dr Chen is the scientific director of UBC Translational Omics Lab in the Victoria General Hospital. He is also the director of Vancouver Island Biobank, and he co-chairs the BC Biobank Network. Dr. Chen’s research focuses on clinical mass spectrometry, biobanking, biomarker validation and clinical implementation.
Financial Disclosures (past 24 months)
: Not reported
